NEW YORK, December 31, 2025, 13:04 ET — Regular session
- Intelligent Bio Solutions shares were up $6.56, or about 160%, at $10.66 in midday trade.
- The company said it signed a manufacturing partnership with Syrma Johari MedTech to scale production of its fingerprint drug-screening reader.
- INBS said the deal targets more than 40% annual production cost savings and about a 20-point gross margin lift.
Intelligent Bio Solutions Inc shares surged on Wednesday after the company said it struck a new manufacturing partnership aimed at lowering costs for its fingerprint-based drug testing device. The stock was up $6.56, or about 160%, at $10.66 by 1:04 p.m. ET.
The announcement matters now because Intelligent Bio is trying to improve its unit economics as it scales. The company said the partnership should drive annual production cost savings of more than 40%, translating to an expected improvement of about 20 percentage points in gross margin. Gross margin is the share of sales left after production costs, before operating expenses.
Syrma Johari’s manufacturing capacity is about four times INBS’ current capacity, the company said, giving it more headroom if demand rises. Intelligent Bio also framed the deal as a way to reduce reliance on a single supplier ahead of a planned U.S. market entry in 2026.
INBS traded between $5.62 and $11.52 during the regular session, compared with Tuesday’s close at $4.10. The company’s market capitalization was about $10.11 million.
Trading volume was unusually heavy for the micro-cap. About 48.13 million shares changed hands versus an average of roughly 34,790, according to Benzinga Pro data.
Syrma Johari operates 14 manufacturing locations and four design and innovation centres across India, Europe and the United States, Intelligent Bio said. The manufacturer is certified to medical-device standards including ISO 13485 and said it is preparing to open a medical-grade plastics facility in India in January 2026.
“Partnering with Syrma Johari is a strategically significant milestone for our business,” said Callistus Sequeira, Intelligent Bio’s vice president of global quality and operations. GlobeNewswire
Intelligent Bio’s system tests traces of sweat left in a fingerprint to screen for recent drug use, including opiates, cocaine, methamphetamine and cannabis, the company said. It is designed to deliver results in under 10 minutes.
The move dwarfed the broader market’s gains, with the S&P 500 and Nasdaq Composite up about 0.3% around midday.
The stock’s volatility follows recent listing-pressure disclosures. A December 15 filing showed Nasdaq warned the company it was out of compliance with the exchange’s $1 minimum bid-price rule, and that INBS implemented a 1-for-10 reverse stock split — combining shares to raise the per-share price — effective late on December 15.
Traders will watch whether the stock can hold onto gains once the initial buying cools, and whether management gives firmer timing on when the manufacturing shift starts showing up in reported margins. The cost-savings targets are forward-looking and hinge on execution and volume.
For now, the rally puts INBS well above the $1 level that underpins its Nasdaq compliance clock. Investors will look for evidence that higher manufacturing capacity turns into orders as the company works toward its planned U.S. launch.
